J. Goldman & Co’s RAPT Therapeutics RAPT Stock Holding History

J. Goldman & Co’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,688	Closed	-$224K	–	448
2023 Q3	$224K	Buy	+1,688	New	+$276K	0.01%	314

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

J. Goldman & Co's RAPT Position: Q2 2022 in Review

J. Goldman & Co sold out of RAPT Therapeutics (RAPT) in Q2 2022, closing a stake of 4,936 shares — an estimated $868K sold.

J. Goldman & Co first reported a position in RAPT in Q4 2021 and held it in 2 quarters. The position peaked at $1.88M in Q4 2021. 84 funds tracked by Wall St. Rank hold RAPT as of Q2 2022.

J. Goldman & Co reported no remaining RAPT Therapeutics position as of Q2 2022 after selling out during the quarter.
J. Goldman & Co sold 4,936 RAPT Therapeutics shares in Q2 2022, an estimated $868K.
J. Goldman & Co first reported a position in RAPT Therapeutics in Q4 2021 and held it in 2 quarters.
J. Goldman & Co's RAPT Therapeutics position peaked at $1.88M in Q4 2021.
84 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2022.

Based on J. Goldman & Co's 13F filing for Q2 2022, filed 15 Aug 2022.